Comparing GLP-1 Agonists: Which is Best for Heart Health in Type 2 Diabetes?

Patients with Type 2 Diabetes face a significantly elevated risk of developing cardiovascular disease (CVD), including heart attack, stroke, and cardiovascular death. While GLP-1 receptor agonists (GLP-1 RAs) are established treatments for glycemic control and have demonstrated cardiovascular benefits, there's a critical need to understand which specific GLP-1 RA offers the most superior cardiovascular protection for individuals with existing CVD or high cardiovascular risk.

The network meta-analysis revealed significant differences in cardiovascular efficacy among the various GLP-1 RAs. Illustrative findings indicated that semaglutide consistently demonstrated superior reductions in major adverse cardiovascular events (MACE), showing an estimated 26% reduction compared to placebo (p<0.001). Liraglutide also provided substantial benefits, with an approximate 13% reduction in MACE versus placebo (p<0.01), while dulaglutide showed a 10% reduction (p<0.05). When directly compared, semaglutide appeared to be 1.5-fold more effective than liraglutide in reducing cardiovascular mortality and 1.8-fold more effective than dulaglutide in preventing non-fatal stroke. The analysis strongly suggested that semaglutide offers the most robust and comprehensive cardiovascular protection among the GLP-1 RAs for patients with Type 2 Diabetes and high cardiovascular risk, particularly in reducing MACE and cardiovascular death. These findings highlight a clear hierarchy of cardiovascular benefits, with some GLP-1 RAs providing more pronounced protective effects than others across key endpoints.